 ProKidney LP, a cellular therapeutics company focused on kidney disease, announced an agreement to merge with special purpose acquisition company SPAC Social Capital Suvretta Holdings Corp. III DNAC, 0.19 in a deal that values the combined company at 2.64 billion. The deal, which will take ProKidney public, is expected to provide 825 million in cash proceeds. 